AEON CEO Marc Forth resigns; Chairman Jost Fischer named interim CEO

AEON Biopharma, Inc.

Marc Forth steps down as President and CEO effective April 4, 2025, to pursue another opportunity.
Forth remains on the board; departure is not due to any disagreement with AEON.
Chairman Jost Fischer appointed Interim CEO; board actively seeking permanent replacement.
AEON expects current cash to fund through Biosimilar BPD Type 2a meeting with FDA in H2 2025.
AEON is a clinical-stage biopharma developing botulinum toxin complex ABP-450 as a BOTOX biosimilar.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Jost Fischer

Interim Chief Executive Officer

AEON · AEON Biopharma, Inc.

Effective: 2025-04-04
Filed: March 27, 2025, 7:59 PM ET

The Board has named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies a replacement CEO.

Departed

Marc Forth

President and Chief Executive Officer

AEON · AEON Biopharma, Inc.

Effective: 2025-04-04
Successor: Jost Fischer
Filed: March 27, 2025, 7:59 PM ET

On March 24, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) was notified by Marc Forth that he intended to resign as the Company’s President and Chief Executive Officer (“CEO”) in order to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jost Fischer was appointed as Interim Chief Executive Officer at AEON Biopharma, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

The Board has named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies a replacement CEO.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Forth resigned as President and Chief Executive Officer at AEON Biopharma, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On March 24, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) was notified by Marc Forth that he intended to resign as the Company’s President and Chief Executive Officer (“CEO”) in order to pursue another opportunity.

View on SEC.gov

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.